As 2025 dawns, bringing both opportunities and challenges, RocRock Bio has successfully closed a Pre - A + financing round of tens of millions of RMB, led by Qingdao Yinghai Antai Equity Investment Partnership (Limited Partnership). The funds raised will accelerate the clinical trials and commercialization of several products, providing a significant boost to the company's future development. Prior to this, RocRock Bio had secured an angel round led by Desheng Capital and a Pre - A round led by Hui Zhu Medical, with a cumulative financing close to 100 million yuan.
RocRock Bio, established in 2021, is a clinically - oriented company specializing in macrophage - based drug development for the treatment of tumors and chronic diseases. It stands out as the only company globally with a unique technology platform that integrates live - cell factor stringing, gene editing, biomaterials, and synthetic biology to engineer macrophages. The company has been honored with titles such as National High - tech Enterprise, Leading Talent of Suzhou Industrial Park (Major Category), Technological Small and Medium - sized Enterprise, Innovative Small and Medium - sized Enterprise, and Jiangsu Private Technology Enterprise, and has undertaken a national "Reveal - list - and - attack" technology project.
Since its inception, RocRock Bio has been committed to the development and clinical application of macrophage - based drugs for the treatment of tumors and chronic diseases, driving the research, development, and industrialization of Chimeric Antigen Receptor Macrophage (CAR - M). The company has established a preparation room in Suzhou Industrial Park that meets GMP standards and (B + A) cleanliness requirements and is currently advancing nine CAR - M cell drug pipelines through multi - center collaborations with multiple global institutions.
RocRock Bio has extensive expertise in macrophage engineering, bioinformatics analysis, and immune cell transdifferentiation. We've grasped essential CAR - M technologies, including engineered macrophage modification, CAR design, and viral vector modification, overcoming the challenge of hard - to - transduce macrophages. Our company is continuously making breakthroughs in solid tumor innovative therapy and steadily advancing several key pipelines
The HER2 - targeted solid tumor pipeline began at Xuzhou Medical University Affiliated Hospital in 2023, enrolling its first patient in December. By the end of 2024, seven patients had been enrolled. In 2025, efforts will concentrate on recruiting HER2+++ patients with abdominal metastasis to expedite the registration clinical phase. Ethical approval has been obtained at Jinan Junxin Tumor Hospital, and somatic cell is in progress, aiming for the first patient enrollment at this center in June 2025.
Peking Union Medical College Hospital's ethics committee has given the green light, and the Beijing Municipal Health Commission is methodically handling the somatic cell filing. The plan is to begin enrolling the first patient by June 2025.
A large hospital in Suzhou, Jiangsu Province, gave the project the green light at the end of 2024. Right now, it's in the ethics review phase, and the aim is to get 3 - 5 patients signed up for the study by 2025.
RocRock Bio's lead pipeline, RR-M01 Injection, is an innovative solid - tumor - targeting drug. It originates from the team's in - depth cancer - mechanism research. With a unique mode of action, RR-M01 Injection can precisely target cancer cells, hindering their growth and spread, while sparing normal cells as much as possible. Unlike conventional therapies, it has demonstrated superior efficacy and lower side - effects in preclinical studies, presenting a more effective and safer treatment alternative for cancer patients. To ensure the IND registration application of RR-M01 Injection proceeds smoothly, RocRock Bio's R&D team worked day and night, carrying out extensive preclinical research with outstanding outcomes. They intend to formally apply for IND registration in 2025 and expect to obtain approval by 2026. RocRock Bio is committed to developing cell - based therapies for solid tumors. Within 5 - 6 years, it aims to successfully launch two innovative drugs, propelling China to the forefront of global macrophage - based solid tumor treatment and establishing itself as a CAR-M leader. The company is dedicated to extending the lifespan of each solid tumor patient by 24 years.
Yinghai Antai, a professional equity investment company, invested in RocRock Bio. Sun Yehao, the investment head, said this move reflects their deep involvement in macrophage therapy and the market's recognition of RocRock Bio's technology and commercial potential. The funds will speed up the IND application for RocRock Bio's core product, RR-M01, and strongly support clinical research for other pipelines, such as the C-MET - targeted pancreatic cancer. The investor values RocRock Bio's leading CAR-M platform, nine diverse pipelines, and its team's extensive macrophage research experience and clinical expertise. This capital-technology integration will enhance China's solid tumor cell therapy, provide solutions for global unmet clinical needs, and help domestic pharmaceutical companies expand internationally.
Dr. Xiushan Yin , Chairman of RocRock Bio, said, "We sincerely thank our shareholders for their recognition and support. Solid tumors and chronic diseases are critical global health challenges. Macrophages offer significant potential in tackling these issues. RocRock Bio, a leader in macrophage drug development with over 20 years of experience, focuses on basic technological innovation to fast-track clinical progress. This funding will facilitate our M01 pipeline's IND application this year and the initiation of the pancreatic cancer clinical trial with Peking Union Medical College Hospital. Additionally, our macrophage drugs for liver and lung fibrosis are progressing well. This successful financing signifies a new chapter for RocRock Bio. We will continue to leverage innovation to advance macrophage drug therapy and deliver more effective and safer treatments to patients worldwide."
No Code Website Builder